Featured
Today as Digestive Disease Week #DDW2023 began in Chicago, Salvo Health announced new additions to its Gastroenterology Advisory Board and senior leadership.
Dr. Mary Rinella, a renowned expert at University of Chicago, co-authored the AASLD guidelines for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Dr. Rinella joins Salvo’s clinical advisors to help oversee the development of “wraparound care” protocols for better detection and treatment of NASH/NAFLD across the US.
Dr. Rinella is a board-certified hepatolgist with over twenty years of experience treating patients with complex liver disease. Dr. Rinella is passionate about using research to advance medicine. She has investigated a broad range of topics within NAFLD, including the use of non-invasive measures to minimize the use of liver biopsy, and the study of new therapies to treat NAFLD, since there is still no FDA-approved treatment. Dr. Rinella has published nearly 150 peer-review articles in prestigious journals, such as Gastroenterology & Hepatology, Gastroenterology, Hepatology, Journal of the American Medical Association (JAMA), The Lancet, and more.
Today also Salvo announces that Dr. Amit H. Sachdev MD, MBA, MS joins the Salvo leadership team as senior clinical advisor, working closely with Salvo CEO Jeffrey Glueck in a part-time capacity. Dr. Sachdev is a double board-certified interventional gastroenterologist who completed his training at New York University, Columbia University and Brigham and Women's Hospital and Harvard Medical School. He is currently on faculty at Mt. Sinai Hospitals in New York. Dr. Sachdev worked at the White House and the Department of Health & Human Services during the COVID 19 response, with particular focus on health care in rural America and ways telehealth can expand access. Dr. Sachdev’s research interests in bariatrics focus on developing novel approaches to fight obesity. Dr. Sachdev earlier in his career conducted IBS research with Dr. Mark Pimentel at Cedars-Sinai and he currently serves on various medical and non medical advisory boards.
Dr. Sachdev will help expand Salvo’s clinical advisory board and protocols as Salvo prepares to launch support for GI practices in additional areas such as NASH and IBD before the end of 2023, as well as deepen Salvo programs for current conditions treated including IBS, GERD, functional dyspepsia, Celiac, and more.
These additions reflect Salvo’s commitment to bring together the top experts in multidisciplinary ways to advance care for chronic gut health conditions that plague over 60 million Americans.
Dr. Rinella joins a distinguished group of physicians and researchers on Salvo’s Gastroenterology Advisory Board including Dr. Emeran Mayer (founder of UCLA’s Brain-Gut Microbiome Center) and Dr. Mark Pimentel (founder of the Pimentel Lab at Cedars-Sinai).
Salvo care teams leverage evidence-based care from the top GI researchers as well as the top experts in behavioral health and lifestyle medicine. Salvo’s Behavioral Health & Lifestyle Medicine Advisory Board includes Dr. Megan Oser (a psychologist who led cognitive behavioral therapy for GI patients at the Brigham and Harvard Medical School, now Director of Behavioral Health for Digestive Medicine at UCLA), Dr. Laura Reigada (member of the Rome Foundation Gastropsych Commitee), Dr. Mark Hyman (co-founder of the Cleveland Clinic Center for Functional Medicine), and other renowned leaders.
GI private practices and GI divisions at hospitals across the US can now partner with Salvo Health to add ancillary services for follow-on care for their patients, reimbursed by insurance under Remote Patient Monitoring (RPM) and Chronic Care Management (CCM) codes. This helps improve patient outcomes and frees up providers to focus on higher acuity patients and procedures. More information on how Salvo helps providers practice at the top of their license is available here.
Initial patient cohorts have shown the power of Salvo’s approach, moving from episodic to continuous care, and giving each chronic patient access to a multidisciplinary dedicated team including a gut-specialist nurse, registered dietitians, and behavioral health specialists. For patients who at intake reported “severe” symptoms, over 95% of patients report material improvement after 4+ weeks of treatment, despite an average of 3+ years of chronic symptoms prior to intake.
At DDW, interested providers and stakeholders should visit the Salvo Health booth (#5130) during the 2023 conference.
Former CEO of Foursquare and former CMO of Travelocity
.png)
.png)
.png)
.png)
